Aligos Therapeutics, Inc.

NasdaqCM:ALGS 주식 보고서

시가총액: US$67.6m

Aligos Therapeutics 관리

관리 기준 확인 3/4

Aligos Therapeutics CEO는 Larry Blatt, Feb2018 에 임명되었습니다 의 임기는 6.75 년입니다. 총 연간 보상은 $ 1.34M, 43.7% 로 구성됩니다. 43.7% 급여 및 56.3% 보너스(회사 주식 및 옵션 포함). 는 $ 1.56M 가치에 해당하는 회사 주식의 2.32% 직접 소유합니다. 1.56M. 경영진과 이사회의 평균 재임 기간은 각각 5.3 년과 3.6 년입니다.

주요 정보

Larry Blatt

최고 경영자

US$1.3m

총 보상

CEO 급여 비율43.7%
CEO 임기6.8yrs
CEO 소유권2.3%
경영진 평균 재임 기간5.3yrs
이사회 평균 재임 기간3.6yrs

최근 관리 업데이트

Recent updates

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Jul 31
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 49% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Jul 16
Aligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash Wisely

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

May 24
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) 27% Dip In Price Shows Sentiment Is Matching Revenues

Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Apr 09
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Feb 23
Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Is Matching Sentiment Around Its Revenues

Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 24
Here's Why We're Watching Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Jul 17
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Mar 11
We Think Aligos Therapeutics (NASDAQ:ALGS) Needs To Drive Business Growth Carefully

Aligos Therapeutics begins 12-week dosing in phase 1b study to treat hepatitis B

Jul 25

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Jul 11
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Feb 02
We're Keeping An Eye On Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Rate

Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Oct 19
Here's Why We're Not Too Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation

Aligos Therapeutics EPS beats by $0.16

May 10

We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

May 01
We're Hopeful That Aligos Therapeutics (NASDAQ:ALGS) Will Use Its Cash Wisely

What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

Jan 16
What Is The Ownership Structure Like For Aligos Therapeutics, Inc. (NASDAQ:ALGS)?

CEO 보상 분석

Larry Blatt 의 보수는 Aligos Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$77m

Jun 30 2024n/an/a

-US$76m

Mar 31 2024n/an/a

-US$100m

Dec 31 2023US$1mUS$587k

-US$88m

Sep 30 2023n/an/a

-US$82m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$83m

Dec 31 2022US$2mUS$549k

-US$96m

Sep 30 2022n/an/a

-US$112m

Jun 30 2022n/an/a

-US$126m

Mar 31 2022n/an/a

-US$136m

Dec 31 2021US$873kUS$549k

-US$128m

Sep 30 2021n/an/a

-US$125m

Jun 30 2021n/an/a

-US$125m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$7mUS$493k

-US$109m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$62m

Dec 31 2019US$674kUS$475k

-US$52m

보상 대 시장: Larry 의 총 보상 ($USD 1.34M )은 US 시장( $USD 653.78K ).

보상과 수익: Larry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Larry Blatt (62 yo)

6.8yrs

테뉴어

US$1,344,458

보상

Dr. Lawrence M. Blatt, also known as Larry, Ph D., MBA, has been Chief Executive Officer and Director at Aligos Therapeutics, Inc. since February 2018 and also has been its Chairman of the Board since June...

리더십 팀

이름위치테뉴어보상소유권
Lawrence Blatt
CEO, President & Chairman of the Board6.8yrsUS$1.34m2.32%
$ 1.6m
Julian Symons
Executive VP & Chief Scientific Officer6.5yrsUS$836.32k0.42%
$ 286.9k
Lesley Calhoun
Executive VP & CFO4.4yrs데이터 없음데이터 없음
Kristina Engeseth
VP and Head of People & Culture2.8yrs데이터 없음데이터 없음
Sushmita Chanda
Executive Vice President & Chief Development Officer6.3yrs데이터 없음데이터 없음
David Smith
Executive VP & Head of Chemical Operations6.3yrs데이터 없음데이터 없음
Tse-I Lin
VP of Early Compound Development & Belgian Site Head2.8yrs데이터 없음데이터 없음
Hardean Achneck
Chief Medical Officerless than a year데이터 없음데이터 없음

5.3yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: ALGS 의 관리팀은 노련하고 경험 (평균 재직 기간 5.3 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Lawrence Blatt
CEO, President & Chairman of the Board6.8yrsUS$1.34m2.32%
$ 1.6m
Carole Nuechterlein
Independent Director6.3yrsUS$12.90k데이터 없음
K. Hirth
Independent Director6.3yrsUS$60.40k0.064%
$ 43.4k
James Scopa
Independent Director3.6yrsUS$67.90k0.20%
$ 133.3k
Heather Preston
Independent Directorless than a year데이터 없음데이터 없음
Margarita Chavez
Independent Directorless than a year데이터 없음데이터 없음
Bridget Martell
Independent Director3yrsUS$52.90k데이터 없음

3.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: ALGS 의 이사회는 경험(평균 재직 기간 3.6 년)으로 간주됩니다.